Publicaciones en las que colabora con Maria Teresa Cedena Romero (7)

2024

  1. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2020

  1. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  2. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma

    Blood Advances, Vol. 4, Núm. 10, pp. 2163-2171

2019

  1. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma

    American Journal of Hematology, Vol. 94, Núm. 8, pp. 853-861